Literature DB >> 18824419

Sensitive and selective liquid chromatography/tandem mass spectrometry methods for quantitative analysis of 1-methyl-4-phenyl pyridinium (MPP+) in mouse striatal tissue.

Mei-Yi Zhang1, Natasha Kagan, Mei-Li A Sung, Margaret M Zaleska, Michael Monaghan.   

Abstract

The systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice produces a reliable and selective degeneration of the nigrostriatal pathway, a hallmark feature of Parkinson's disease (PD). Determining the brain concentrations of 1-methyl-4-phenyl pyridium (MPP+), the neurotoxic metabolite of MPTP, is critical for evaluating drugs designed to potentially treat PD. We have developed sensitive and specific quantitative methods for the determination of MPP+ in mouse striatal tissue by liquid chromatography/tandem mass spectrometry. The separations were carried out based on reversed phase chromatography or cation exchange chromatography with volatile elution buffer. Neutralizing the brain sample with 0.2M phosphate buffer successfully solved a high-performance liquid chromatography (HPLC) peak tailing of MPP+ in brain extracts with 0.4M perchloric acid (HClO4) under the reversed phase HPLC conditions, which significantly improved the sensitivity of the method. The HPLC peak shape of MPP+ using cation exchange chromatography was not affected by the pH of the samples. Optimization of electrospray ionization (ESI) conditions for the quaternary ammonium compound MPP+ established the limits of detection (LOD) (S/N=3) at 0.34pg/mg tissue and 0.007pg/mg tissue (5microl of injection) using the reversed phase liquid chromatography/tandem mass spectrometry (LC/MS/MS) and the cation exchange LC/MS/MS, respectively. Both methods were selective, precise (%R.S.D.<6%), and sensitive over a range of 0.001-1ng/mg tissue. The cation exchange method showed greater sensitivity and tolerance to low pH samples than the reversed phase method. The developed methods were applied to monitoring changes in MPP+ concentrations in vivo. Two reference agents, R-(-) Deprenyl and MK-801, known to alter the concentration of MPP+ in MPTP treated mice were evaluated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824419     DOI: 10.1016/j.jchromb.2008.08.030

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Authors:  Aditiben Patel; Giuseppe V Toia; Kalea Colletta; Brinda Desai Bradaric; Paul M Carvey; Bill Hendey
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

2.  Liquid chromatographic-electrospray mass spectrometric determination of 1-methyl-4-phenylpyridine (MPP+) in discrete regions of murine brain.

Authors:  Andreas Lehner; Margaret Johnson; Tyrell Simkins; Kelly Janis; Keith Lookingland; John Goudreau; Wilson Rumbeiha
Journal:  Toxicol Mech Methods       Date:  2010-12-13       Impact factor: 2.987

3.  Alteration of selective neurotransmitters in fetal brains of prenatally alcohol-treated C57BL/6 mice: quantitative analysis using liquid chromatography/tandem mass spectrometry.

Authors:  Youssef Sari; Loubna A Hammad; Marwa M Saleh; George V Rebec; Yehia Mechref
Journal:  Int J Dev Neurosci       Date:  2010-02-01       Impact factor: 2.457

4.  The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.

Authors:  Lin W Hung; Victor L Villemagne; Lesley Cheng; Nicki A Sherratt; Scott Ayton; Anthony R White; Peter J Crouch; SinChun Lim; Su Ling Leong; Simon Wilkins; Jessica George; Blaine R Roberts; Chi L L Pham; Xiang Liu; Francis C K Chiu; David M Shackleford; Andrew K Powell; Colin L Masters; Ashley I Bush; Graeme O'Keefe; Janetta G Culvenor; Roberto Cappai; Robert A Cherny; Paul S Donnelly; Andrew F Hill; David I Finkelstein; Kevin J Barnham
Journal:  J Exp Med       Date:  2012-04-02       Impact factor: 14.307

5.  The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.

Authors:  David I Finkelstein; Jessica L Billings; Paul A Adlard; Scott Ayton; Amelia Sedjahtera; Colin L Masters; Simon Wilkins; David M Shackleford; Susan A Charman; Wojciech Bal; Izabela A Zawisza; Ewa Kurowska; Andrew L Gundlach; Sheri Ma; Ashley I Bush; Dominic J Hare; Philip A Doble; Simon Crawford; Elisabeth Cl Gautier; Jack Parsons; Penny Huggins; Kevin J Barnham; Robert A Cherny
Journal:  Acta Neuropathol Commun       Date:  2017-06-28       Impact factor: 7.801

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.